Shots:

• The approval is based on the safety & efficacy results from the P-III (ECZTRA 1/2 & 3) trials to evaluate Adbry (300mg, q2w) with/out TCS in ~2,000 adult patients aged ≥18yrs. with AD who were candidates for systemic therapy. The therapy is expected to be available in Feb 2022
• Adbry will be available in a 150 mg/mL SC PFS with an initial dose of 600mg followed by (300mg, q2w). Additionally, the company plans to launch the Adbry advocate program to support US patients through treatment with Adbry
• Adbry is the 1st FDA approved biologic that specifically binds & inhibits IL-13 cytokine & marks 5th global regulatory approval for tralokinumab in 2021 which is marketed under the brand name Adtralza (ex-US)

Ref: LEO Pharma | Image: LEO Pharma